Evidence map›Paper›PMID 38737656›Full record

ReviewJournal of medicine and life2024

Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis.

Yudith Annisa Ayu Rezkitha, Nur Syahadati Retno Panenggak, Maria Inge Lusida, Raissa Virgy Rianda, Isna Mahmudah, Aditya Doni Pradana, Tomohisa Uchida, Muhammad Miftahussurur

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of medicine and life, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yudith Annisa Ayu RezkithaDoctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Nur Syahadati Retno PanenggakHelicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
Maria Inge LusidaInstitute of Tropical Disease, Indonesia-Japan Collaborative Research Center for Emerging and Re-Emerging Infectious Diseases, Universitas Airlangga, Surabaya, Indonesia.
Raissa Virgy RiandaDepartment of Child Health, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Isna MahmudahHelicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
Aditya Doni PradanaDepartment of Emergency Services, Kendal Islamic Hospital, Kendal, Indonesia.
Tomohisa UchidaDepartment of Molecular Pathology, Faculty of Medicine, Oita University, Yufu, Japan.
Muhammad MiftahussururHelicobacter pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most frequent types of cancer, with high incidence rates and mortality globally. The extended timeframe for developing CRC allows for the potential screening and early identification of the disease. Furthermore, studies have shown that survival rates for patients with cancer are increased when diagnoses are made at earlier stages. Recent research suggests that the development of CRC, including its precancerous lesion, is influenced not only by genetic factors but also by epigenetic variables. Studies suggest epigenetics plays a significant role in cancer development, particularly CRC. While this approach is still in its early stages and faces challenges due to the variability of CRC, it shows promise as a potential method for understanding and addressing the disease. This review examined the current evidence supporting genetic and epigenetic biomarkers for screening and diagnosis. In addition, we also discussed the feasibility of translating these methodologies into clinical settings. Several markers show promising potential, including the methylation of vimentin (

Indexed as

Biomarkers, TumorColorectal NeoplasmsEarly Detection of CancerEpigenesis, GeneticSeptinsDNA MethylationHumansSyndecan-2VimentinBiomarkers, TumorSDC2 protein, humanSEPTIN9 protein, humanSeptinsSyndecan-2Vimentincancercolorectal cancerdiagnostic biomarkersepigenetic biomarkersgenetic biomarkers

Identifiers

PMID38737656
PMCPMC11080499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.